Psoriasis is a chronic inflammatory skin disorder that affects about 2-3% of the population. It is triggered by the immune system, and new insights into immune processes have thrown up a number of exciting drug targets.
This article was first published by Nature Reviews Drug Discovery, which has full responsibility for all editorial content. It is a NatureVideo production and was reproduced with permission. The editorial advisor is Manfred Kopf; animation by Arkitek Scientific. This content is editorially independent of sponsors.
Produced with support from Eli Lilly and Company.